Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Bullboard Posts
Post by larooon Oct 29, 2015 6:13pm
190 Views
Post# 24241078

IN financial bashers

IN financial bashersTo all of you who probably never graduated from high school and really don't understand financial statements ( See JerOn, Harperhater & NYfootballer)......... here's a small education on Inmed. > > To start let's address the earlier post on the non-capital loss carry forward of $19,014,891.00 .. > This is the amount carried forward to offset future taxable income in Canada until 2035... > Which inmed is currently NOT claiming as the revenues to date are all investor backed..... > The fact is they actually had a net operating loss of $4,292,637 for the past year. > Which was offset from the private placement deals totaling $2,540,000, along with additional shares issued totaling another $1,918,000, leaving $166,565 left in cash assets as of June 30 2015 > Also don't forget the grants received for Glaucoma studies at UBC. > So for those wanting to bash Inmed saying they're going broke, please get your facts straight before posting pure BS > The brain trust have a plan and know what they're doing. Please read the latest release from Paul Brennan. Read between the lines at how fast this company is about to grow. > Ask yourself.... do you honestly think that this company is going belly up with the team they have assembled & the kind of scientific news being released right now? > To the uninformed and perpetually miserable/negative posters on this board...if you don't believe in what IN is doing, for the sake of all investors who actually do believe in this company, just sell your shares and get lost.
Bullboard Posts